Skip to content
Screener

Viking Therapeutics VKTX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$1.39M+123%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$1.03M-1.4%
VAN
Vivani MedicalVANI
$1.78M+35.9%
Altimmune logo
AltimmuneALT
$265K+8.2%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$178K+36.9%
Wave Life Sciences logo
Wave Life SciencesWVE
$3.51M-56.9%

Other financials

Income statement

See full
Revenue-
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$4B-6.9%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0.0×
Current ratio5.7×-38.5×

Where this comes from

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.

Filed
Apr 29, 2026, 9:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-193315
Line itemMarch 31,2026December 31,2025
Current liabilities:
Accounts payable$67,183$53,251
Other accrued liabilities39,14223,279
Lease liability, current137
Total current liabilities106,32576,667
Total liabilities106,32576,667
Commitments and contingencies (Note 7)
Stockholders’ equity:

Item 1. Financial Statements

FAQ

What is Viking Therapeutics's operating lease liabilities (current)?
Viking Therapeutics (VKTX) reported operating lease liabilities (current) of $0 in Q1 2026.
How has Viking Therapeutics's operating lease liabilities (current) changed year-over-year?
Viking Therapeutics's operating lease liabilities (current) decreased by 100.0% year-over-year, from $498K to $0.
What is the long-term trend for Viking Therapeutics's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Viking Therapeutics's operating lease liabilities (current) has grown at a -16.1% compound annual growth rate (CAGR), from $330K to $137K.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Viking Therapeutics's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude